NTLA: Multiplikator Forward P/S Intellia Corp

Lambang korporat lan logo Intellia (NTLA)

Intellia Therapeutics (NTLA) is developing scientific alliances with biotech leaders to create therapies for rare pathologies. The current forward P/S level on the GURU.Markets dynamic chart shows 25.80, which determines the current status of the parameter. The asset is independent of GDP cycles, relying instead on the success of clinical trials, while growth is based on organic R&D and support from pharmaceutical industry behemoths.

Intellia Therapeutics, Inc. - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep NTLA (periode 04.07.2022 - 15.11.2026)

Rincian metrik lan analitis perusahaan intelliatx.com (NTLA)

Pambiji fundamental:intelliatx.com NTLA
Sampel barang Intellia Therapeutics

Intellia Therapeutics (NTLA) is scaling CRISPR/Cas9 technologies to create global blockbusters for the treatment of rare liver pathologies. The forward P/S ratio measures the market value of the business relative to projected annual sales volume. By analyzing the projected price-to-sales ratio on GURU.Markets, an investor separates market noise from the actual growth in revenue expectations. The dynamics of this indicator determine the balance between return potential and the asset's sensitivity to fundamental risks.

Analisis pesaing

Multiplikator Forward P/S TEM (Tempus Labs)|Qiagen N.V. - Rasio rega marang prakiraan pendapatan|IONS - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep repligen.com|RNA: Multiplikator Forward P/S|CRISPR Therapeutics Inc (CRSP) - Multiplikator Forward P/S|WGS (GeneDx Holdings) - Multiplikator Forward P/S|RARE: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan BEAM (Beam Therapeutics Corp)|SRPT: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S TWST (Twist Bioscience Inc)|Rasio kapitalisasi marang dodolan sing dikarepake 10x Genomics Corp (TXG)|Stoke Corp - Multiplikator Forward P/S|BLFS (BioLife) - Kapitalisasi marang prakiraan pendapatan|wavelifesciences.com (WVE) - Rasio rega marang prakiraan pendapatan|MAZE - Rasio kapitalisasi marang dodolan sing dikarepake|SION (Sionna Therapeutics, Inc.) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Prime Medicine Corp (PRME)|Multiplikator Forward P/S TSHA|Multiplikator Forward P/S uniQure N.V. (QURE)|Rasio rega marang prakiraan pendapatan MeiraGTx Holdings plc MGTX|RGNX: Kapitalisasi marang prakiraan pendapatan|Solid Biosciences Inc - Multiplikator Forward P/S|OCGN - Multiplikator Forward P/S|PACB: Multiplikator Forward P/S|BNTC - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Design Therapeutics, Inc.|RCKT: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan FDMT (4D Molecular Therapeutics, Inc.)|Lexeo Therapeutics, Inc. - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Korro Bio, Inc. KRRO|EDIT: Kapitalisasi marang prakiraan pendapatan|SLN - Rasio rega marang prakiraan pendapatan|Prakiraan rega marang pendapatan ProQR Therapeutics (PRQR)|CDXS (Codexis Bio) - Multiplikator forward rega marang pendapatan|Sangamo Therapeutics Inc. (SGMO) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Nautilus Bio|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Metagenomi Therapeutics MGX|Rasio rega marang prakiraan pendapatan Precision BioSciences (DTIL)|GBIO - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S BOLD (Boundless Bio, Inc)|XCUR - Multiplikator forward rega marang pendapatan|IMNN - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Phio Pharmaceuticals Corp|MBIO: Multiplikator Forward P/S|TransCode (RNAZ) - Multiplikator Forward P/S|BNGO (Bionano) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Applied DNA Sciences, Inc. APDN|Multiplikator Forward P/S BLUE|ImmunoPrecise Antibodies Ltd - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Omega Therapeutics OMGA|OMIC: Kapitalisasi marang prakiraan pendapatan|RGLS: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan SYRS (Syros Pharmaceuticals, Inc.)|Telesis Bio, Inc. (TBIO) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan TCON (TRACON)|Rasio rega marang prakiraan pendapatan Unity Biotechnology, Inc.